1. Search Result
Search Result
Results for "

Immunogenic Peptide

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

21

Peptides

Cat. No. Product Name Target Research Area
  • HY-P6355

    Peptides Inflammation/Immunology
    CAP1-6D is an agonist peptide for cytotoxic T cell (CTL), that enhances the immunogenicity of the CAPI peptide, and stimulates T cell responses .
  • HY-P3486

    Peptides Inflammation/Immunology Cancer
    GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .
  • HY-P3488

    Peptides Inflammation/Immunology Cancer
    GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .
  • HY-P3487

    Peptides Inflammation/Immunology Cancer
    GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research .
  • HY-P3485

    Peptides Cancer
    GAGGVGKSAL is a wild-type KRAS G12D 10mer peptide. GAGGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research .
  • HY-P3719
    MOG(35-55) amide, mouse, rat
    1 Publications Verification

    CCR Inflammation/Immunology
    MOG peptide (35-55) is a fragment 35-55 of myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide. MOG peptide (35-55) is specific to expanded CD4 + T cells, and induces experimental autoimmune encephalomyelitis (EAE) in animal model .
  • HY-P10020

    hTERT (660–689)

    Peptides Cancer
    Alrefimotide is a hTERT-derived immunogenic peptide. Alrefimotide has a sequence of ALFSVLNYERARRPGLLGASVLGLDDIHRA. Alrefimotide can be used in cancer immunotherapy research .
  • HY-P5273

    Peptides Inflammation/Immunology
    FLAG-Cys is a Flag peptide with a Cys residue. FLAG-Cys has immunogenicity .
  • HY-P1610

    PD-1/PD-L1 Cancer
    Asudemotide (S-588410) is a peptide of human DEP domain-containing protein 1A. Asudemotide is an immunostimulant. Asudemotide has a sequence of H-Glu-Tyr-Tyr-Glu-Leu-Phe-Val-Asn-Ile-OH. Asudemotide induces a tumor immune response in esophageal cancer. .
  • HY-P1870

    Peptides Inflammation/Immunology
    OVA sequence (323-336) is a cognate helper T-lymphocyte peptide that is employed to enhance CTL epitope immunogenicity.
  • HY-P10701

    Biochemical Assay Reagents Inflammation/Immunology Cancer
    Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology .
  • HY-P1778

    HPV Infection
    HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .
  • HY-P1778A

    HPV Infection
    HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .
  • HY-P1684

    FOXP3 inhibitor P60

    NF-κB Nuclear Factor of activated T Cells (NFAT) Infection Inflammation/Immunology Cancer
    Peptide P60 is a FOXP3 inhibitor. Peptide P60 can enter cells, inhibit the nuclear translocation of FOXP3, and diminish its ability to suppress the transcription factors NF-κB and NFAT. Peptide P60 can inhibit the immunosuppressive activity of regulatory T cells (Treg) derived from mice and humans, and enhance the stimulation of effector T cells in vitro. Peptide P60 can induce a lymphoproliferative autoimmune syndrome with pathological manifestations resembling those reported in scurfy mice lacking functional Foxp3. Peptide P60 can enhance the immunogenicity of cancer and viral vaccines.
  • HY-P10295

    MDM-2/p53 Cancer
    p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system .
  • HY-P10371

    Reactive Oxygen Species Thrombopoietin Receptor Inflammation/Immunology Cancer
    PKHB1 is a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS production, intracellular Ca 2+ accumulation, as well calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation through immunogenic cell death induction in breast cancer cells .
  • HY-P5295

    Fluorescent Dye Others
    Cy3-Ova (323-339) is an Cy3 labled OVA Peptide (323-339) (HY-P0286). Cy3 is a fluorescent dye belonging to the Cyanine family and is a fluorescent light product of Cy5. Cyanine is commonly used in fluorescence microscopy, cell imaging, and molecular biology experiments. OVA Peptide (323-339) represents the T and B cell epitopes of ovalbumin (OVA). OVA Peptide (323-339) has limited immunogenic efficacy in activating OVA-sensitized and attacked mouse spleen cells .
  • HY-P5471

    [Leu27]-Melan-A, MART-1 (26-35)

    Peptides Others
    Melan-A/MART-1 analog ([Leu27]-Melan-A, MART-1 (26-35)) is a biological active peptide. (This Melan-A (26-35) analog, Leu substituted for Ala at position 27, shows better HLA-A*0201 binding properties as well as better immunogenicity and antigenicity than the natural Melan-A (26-35).Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
  • HY-P10491

    Peptides Cancer
    MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. MAGE A4 (230-239) is an immunogenic epitope that can activate T cells and trigger the killing of tumor cells expressing MAGE-A4. MAGE A4 (230-239) is used in the development of next-generation T cell-based immunotherapies .
  • HY-P10593

    Transmembrane Glycoprotein Influenza Virus Cancer
    Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
  • HY-P2459

    MHC Neurological Disease
    MOG (35-55), human is a component of CNS myelin. MOG (35-55), human is different from mMOG (35-55) by a proline for serine substitution at position 42. MOG (35-55), human is also immunogenic via bind to H-2b class II MHC and recognized by T cells, but not encephalitogenic, and is only partially cross-reactive with mMOG35–55. MOG (35-55), human induces minimal clinical signs of EAE relative to the rodent peptide .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: